Publication | Closed Access

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial

Unresectable LeiomyosarcomaFirst-line TherapySurgical OncologyMalignant DiseaseOpen-label Phase 3MedicinePathologyCancer TreatmentOncologyRadiation Oncology